Clinical trial · Interventional
Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors
Management of Children Aged Less Than 3 Years With Brain Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after chemotherapy may kill any remaining tumor cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with or without radiation therapy works in treating children with brain tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain and Central Nervous System Tumors | — | UNRESOLVED | — |
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carboplatin | Drug | Carboplatin | ALIAS |
| cisplatin | Drug | Cisplatin | ALIAS |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| methotrexate | Drug | Methotrexate | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
| vincristine sulfate | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (9)
- measure
- Response rate
- measure
- Event-free survival
- measure
- Local recurrence or occurrence of CNS metastases
- measure
- Quality of survival
- measure
- Tolerance
- measure
- Long-term toxicity
- measure
- Proportion of patients requiring radiotherapy
- measure
- Prognosis of children who receive both chemotherapy and radiotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 3 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Diagnosis of 1 of the following:
* Brain stem tumor (histological confirmation not required)
* Histologically confirmed primary intracranial brain tumor of 1 of the following histologies:
* Anaplastic (malignant) astrocytoma
* Glioblastoma
* Anaplastic (malignant) oligodendroglioma
* Ependymoma
* Anaplastic (malignant) ependymoma
* Anaplastic (malignant) oligoastrocytoma
* Choroid plexus carcinoma
* Astroblastoma
* Polar spongioblastoma
* Gliomatosis cerebri
* Anaplastic (malignant) ganglioglioma
* Pineoblastoma
* Mixed pineocytoma or pineoblastoma
* Medulloepithelioma
* Neuroblastoma
* Ependymoblastoma
* Primitive neuroectodermal tumors (PNETs), including medulloblastoma or cerebral or spinal PNETs
* Has undergone surgery or biopsy of the tumor within the past 2-4 weeks
PATIENT CHARACTERISTICS:
* No concurrent unrelated disease, including hematological or renal disease, that would preclude study treatment
PRIOR CONCURRENT THERAPY:
* No prior chemotherapy or radiotherapy
* Prior steroids allowed
* No concurrent steroids as anti-emetics
* Concurrent steroids allowed for control of tumor-related symptomsReferences
Publications (0)
Data not yet available